Goldman Sachs Group Inc Lipocine Inc. Transaction History

Goldman Sachs Group Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 14, 2024	BUY	$0.73 - $1.34 $18,944 - $34,775	25,952 New	25,952 $21,000
Q2 2022 Aug 15, 2022	SELL	$0.73 - $1.34 $45,743 - $83,968	-62,663 Reduced 70.71%	25,952 $21,000
Q1 2022 May 16, 2022	BUY	$0.89 - $1.85 $66,240 - $137,691	74,428 Added 524.62%	88,615 $121,000
Q4 2021 Feb 14, 2022	BUY	$0.99 - $1.2 $14,045 - $17,024	14,187 New	14,187 $14,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $335M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.